Epicentre is launching a prospective cohort study in the Békourou health district to evaluate the in vivo effectiveness of the sulfadoxine-pyrimethamine and amodiaquine (SPAQ) combination used in seas...

Company Description: Created by Médecins Sans Frontières (MSF) in 1986, Epicentre carries out field epidemiology, training and medical research in support of MSF's humanitarian objectives. We have 3 r...

Background HIV remains a major public health challenge globally, including in the Central African Republic (CAR). Despite progress in awareness, prevention and access to antiretroviral therapy (ART), ...

Company Description: Created by Médecins Sans Frontières (MSF) in 1986, Epicentre carries out field epidemiology, training and medical research in support of MSF's humanitarian objectives. We have 3 r...

Alors que l’épidémie de maladie Ebola à virus Bundibugyo continue de se propager en République démocratique du Congo (RDC), Médecins Sans Frontières (MSF) et Epicentre, son centre de recherche en épid...

Objectives To estimate the carbon footprint of a vaccine trial conducted in Uganda and to identify opportunities to reduce greenhouse gas emissions in future trials. Design Retrospective carbon footp...

We developed a pragmatic approach to calibrating computer-aided detection (CAD) thresholds in a tuberculosis (TB) active case finding (ACF) project in the Philippines, assessing its feasibility and ac...

Background The expanding volume and increasing complexity of clinical research in East Africa, driven by emerging and re-emerging infectious diseases, has increased the need for strong regulatory moni...

Background Globally, about 2.3 million neonates die annually, most of them in low-resource and conflict-affected countries. In Yemen, ongoing humanitarian crises put children at continued risk, with n...

The ongoing 2026 Bundibugyo virus disease (BVD) public health emergency of international concern in DR Congo and Uganda has exposed gaps in preparedness for non-zairense orthoebolaviruses. With BVD va...

On May 15, the Democratic Republic of the Congo (DRC) declared its 17th Ebola virus disease outbreak, caused by the Bundibugyo virus, for which there is currently no vaccine or specific treatment. In ...

Background The 2018–20 Ebola virus disease outbreak in the Democratic Republic of the Congo (DRC) was the country’s largest, and the second largest globally, amid armed conflict and community mistrust...

While the first malaria vaccines, RTS,S/AS01and R21/Matrix-M™, mark a major step forward in the fight against this disease, questions remain about the best administration strategy to maximize their im...

Background A large measles outbreak occurred in Yakusu Health Zone, Democratic Republic of the Congo, between January 2018 and June 2019. We aimed to estimate the magnitude, mortality burden, and vacc...

The Coalition for Epidemic Preparedness Innovations.

10.1542/6388819904112Video AbstractPEDS-VA_2025-0723576388819904112OBJECTIVES. Pediatric Early Warning Systems (PEWSs) have been used to predict adverse outcomes among hospitalized patients, though ev...

Despite its proven effectiveness, hydroxyurea remains difficult to access and underused in sub-Saharan Africa. Two studies conducted by Epicentre and Médecins Sans Frontières (MSF) aim to document the...

On May 15, 2026, the Democratic Republic of Congo's Ministry of Health officially declared an Ebola disease outbreak in the northeast of the country, where Médecins Sans Frontières (MSF) teams are ope...

YouTube video by La Fondation MSF

YouTube video by Epicentre - MSF

Background The Central African Republic (CAR), a fragile and conflict-affected setting, has one of the highest maternal mortality ratios in the world. Complications of unsafe abortion, while preventab...

YouTube video by Epicentre - MSF

Cholera remains a significant public health burden in sub-Saharan Africa, but the mechanisms of continental and regional spread remain undefined. Here, the authors investigate recent patterns of spread using Vibrio cholerae genomic surveillance data collected by a consortium of seven African Union member states from 2019-2024.

In Pakistan, Epicentre is conducting a study to better understand how new, all oral, shorter treatments for multidrug-resistant/rifampicin‑resistant tuberculosis (MDR/RR-TB) are implemented in real-world settings. These treatment regimens have already proven effectiveness in clinical trials, and are recommended by the World Health Organisation (WHO), but what about once they leave the controlled setting of a trial? The study explores their impact on patients' lives, their feasibility for healthcare providers, and their acceptability in a context where challenges remain numerous: treating children and pregnant women, managing highly resistant forms of TB, and monitoring the emergence of new resistance.

Objectives The COVID-19 pandemic threatened global HIV Test and Treat Efforts. We assessed whether it affected (1) the number of antiretroviral therapy (ART) initiations and (2) the proportion of time...

YouTube video by MSF Access

YouTube video by Epicentre - MSF

Advanced HIV patients face high mortality, often from invasive bacterial infections (IBI), while rising antimicrobial resistance (AMR) threatens treat…

Discover Epicentre's current studies on pediatric cancers

Compared with the standard yellow fever vaccine dose, a dose of 500 IU did not meet the non-inferiority criterion, suggesting that minimum dose requirements in adults are not generalisable to infants....

The assure IgM RDT showed higher sensitivity for identifying hepatitis E than PCR and similar specificity to IgM ELISA, supporting its use in surveillance.